C12Y 302/01046
Galactosylceramidase
Official title: Galactosylceramidase (3.2.1.46)
C12Y302/01046 (Galactosylceramidase) appears on 31 US grants and 63 published applications in this corpus.
Search patents in C12Y- Granted patents
- 31
- Published applications
- 63
- Assignees
- 32
- Inventors
- 92
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 3 |
| 2012 | 0 | 1 |
| 2013 | 1 | 4 |
| 2014 | 1 | 4 |
| 2015 | 4 | 2 |
| 2016 | 0 | 3 |
| 2017 | 3 | 3 |
| 2018 | 2 | 6 |
| 2019 | 2 | 3 |
| 2020 | 2 | 5 |
| 2021 | 2 | 1 |
| 2022 | 4 | 8 |
| 2023 | 0 | 4 |
| 2024 | 5 | 2 |
| 2025 | 3 | 7 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment of Krabbe disease with umbilical cord blood transplantion (UCBT) and increased galactocerebrosidase (GALC) expression14 Apr 2026US 12,599,636 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Vector compositions and methods of using same for treatment of lysosomal storage disorders9 Dec 2025US 12,492,412 B2M6P Terapeutics (Switzerland) LLC
- CNS delivery of therapeutic agents9 Sep 2025US 12,409,210 B2Takeda Pharmaceutical Company Limited
- Optimized GALC genes and expression cassettes and their use15 Jul 2025US 12,359,181 B2The Trustees of the University of Pennsylvania
- Methods and compositions for CNS delivery of arylsulfatase A17 Dec 2024US 12,168,041 B2Takeda Pharmaceutical Company Limited
- Compositions comprising modified human galactocerebrosidase24 Sep 2026US 2026/0286330 A1M6P Therapeutics, Inc.
- Treatment of krabbe disease with umbilical cord blood transplantation (ucbt) and increased galactocerebrosidase (galc) expression6 Aug 2026US 2026/0224639 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Reversed micelles for delivery of hydrophilic drugs8 Jan 2026US 2026/0007770 A1Consiglio Nazionale Delle Ricerche
- Cns delivery of therapeutic agents11 Dec 2025US 2025/0375506 A1Takeda Pharmaceutical Company Limited
- Compositions and methods for treating metachromatic leukodystrophy disease and related disorders17 Jul 2025US 2025/0228907 A1The Children’s Hospital of Philadelphia
Most cited
By later US patents
- Cleavable lipids30US 9,717,690 B2RaNA Therapeutics, Inc. · 2017
- Yarrowia lipolytica and Pichia pastoris HAC1 nucleic acids20US 8,026,083 B2Oxyrane UK Limited · 2011
- Glycosylation of molecules14US 8,597,906 B2Oxyrane UK Limited · 2013
- Methods and compositions for CNS delivery of iduronate-2-sulfatase13US 9,220,677 B2Shire Human Genetic Therapies, Inc. · 2015
- Microorganisms genetically engineered to have modified N-glycosylation activity11US 9,206,408 B2Oxyrane UK Limited · 2015